Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;30(4):1430-1439.
doi: 10.1038/s41380-024-02753-9. Epub 2024 Oct 9.

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

Collaborators, Affiliations

Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology

Clara Vila-Castelar et al. Mol Psychiatry. 2025 Apr.

Abstract

Glial reactivity may contribute to sex/gender differences in Alzheimer's disease (AD) pathophysiology. Here, we investigated the differential effect of cerebrospinal fluid (CSF) glial markers on AD pathology and neurodegeneration by sex/gender among cognitively unimpaired older adults at increased risk of developing AD. We included 397 participants from the ALFA+ cohort with CSF Aβ42/40, p-tau181, sTREM2, YKL40, and GFAP, magnetic resonance imaging-based hippocampal volume (n = 299), and amyloid burden (centiloids) measured with [18F] flutemetamol positron emission tomography (n = 341). We ran multiple linear regression models to assess the association between glial markers, AD pathology and hippocampal volumes and their interaction with sex/gender, using False Discovery Rate to correct for multiple comparisons. Glial markers significantly contributed to explain amyloid burden, tau pathology, and hippocampal volumes, beyond age and/or primary AD pathology in a sex/gender-specific manner. Compared to men, women showed increased amyloid burden (centiloids) and CSF p-tau181 with increasing levels of sTREM2 and YKL40, and YKL40 and GFAP, respectively. Compared to women, men with greater tau burden showed lower hippocampal volumes as CSF YKL40 levels increased. Overall, our findings suggest that glial reactivity may contribute to sex/gender differences in AD progression, mostly, downstream amyloid. Further research identifying sex/gender-specific temporal dynamics in AD development is warranted to inform clinical trials.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CV-C, MA, EP, PA-D, GO, KB, JD-G, CF, KFC and EMAU report no conflict of interest. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). OG-R has given lectures in symposia sponsored by Roche Diagnostics, and receives support for research (to the institution) from F- Hoffmann La Roche. GK is a full‑time employee of Roche Diagnostics GmbH. CQ-R is a full‑time employee of Roche Diagnostics International Ltd. MS-C has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A, Eli Lilly and Amirall, he has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L. He was granted with a project funded by Roche Diagnostics International Ltd. All payments were made to the institution (BBRC). He received in-kind support for research (to the institution) from Roche Diagnostics International Ltd, Avid Radiopharmaceuticals, Inc., Eli Lilly and Janssen Research & Development.

Figures

Fig. 1
Fig. 1. Scatterplots showing the 3-way interactions within the A/T/N framework.
Panels AC illustrate the 3-way interactions in scatter plots. Aβ42/40 and p-tau181 values were divided by median to the higher (Aβ42/40 < 0.08; p-tau181 > 14.4) vs. lower (Aβ42/40 ≥ 0.08; p-tau181 < 14.4) categories. Aβ42/40 CSF β-amyloid, p-tau181 CSF phosphorylated-tau181, GFAP CSF glial fibrillary acidic protein, YKL40 CSF chitinase-3-like protein 1.
Fig. 2
Fig. 2. Forest plots with standardized coefficients showing the main and interactive effects of sex/gender and glial markers on the A, T, and N.
Forest plots displaying the standardized regression coefficients (95% confidence intervals) for the multiple regression models with Aβ42/40 (A), p-tau181 (T) and hippocampal volume (N) as the dependent variables. Models with A included age and APOE ε4 as covariates. Models with T included age and Aβ42/40 as covariates. Models with N included age, Aβ42/40, and p-tau181 as covariates. A amyloid, T tau, N neurodegeneration, sTREM2 CSF soluble triggering receptor expressed on myeloid cells 2, GFAP CSF glial fibrillary acidic protein, YKL40 CSF chitinase-3-like protein 1.

Comment in

References

    1. Mielke MM, Aggarwal NT, Vila‐Castelar C, Agarwal P, Arenaza‐Urquijo EM, Brett B, et al. Consideration of sex and gender in Alzheimer’s disease and related disorders from a global perspective. Alzheimers Dement. 2022;18:2707–24. - PMC - PubMed
    1. Arenaza-Urquijo EM, Boyle R, Casaletto K, Anstey KJ, Vila-Castelar C, Colverson A, et al. Sex and gender differences in cognitive resilience to aging and Alzheimer’s disease. Alzheimers Dement. 2024;20:5695–5719. - PMC - PubMed
    1. Sundermann EE, Biegon A, Rubin LH, Lipton RB, Mowrey W, Landau S, et al. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy. Neurology. 2016;86:1368–76. - PMC - PubMed
    1. Digma LA, Madsen JR, Rissman RA, Jacobs DM, Brewer JB, Banks SJ. Women can bear a bigger burden: Ante-and post-mortem evidence for reserve in the face of tau. Brain Commun. 2020;2:fcaa025. - PMC - PubMed
    1. Vila-Castelar C, Tariot PN, Sink KM, Clayton D, Langbaum JB, Thomas RG, et al. Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer’s disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial. Alzheimers Dement. 2022;18:2272–82. - PMC - PubMed

MeSH terms